Delivery Order SPE2DR25D7005-SPE2DR26F3EZG
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,032.38 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 29, 2026, with an ultimate completion date of January 30, 2026. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Procainamide is an antiarrhythmic medication used to treat abnormal heart rhythms, making this a...
- The Defense Logistics Agency awarded a delivery order valued at $3,056.93 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 18, 2026, with completion targeted for January 20, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Procainamide is an antiarrhythmic medication used in cardiac care, reflecting the broad...
- The Defense Logistics Agency awarded a delivery order valued at $2,998.81 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 28, 2026, with completion scheduled for January 29, 2026. This firm fixed-price, competitively awarded contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Procainamide is an antiarrhythmic medication used in military and federal healthcare settings to...
- The Defense Logistics Agency awarded a delivery order valued at $6,764.42 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 16, 2026. This is a firm fixed-price contract with an ultimate completion date of January 20, 2026, and represents a non-competitive, non-set-aside award. The contractor will perform from its corporate office in Conshohocken, Pennsylvania. Procainamide is a cardiac antiarrhythmic medication used to treat irregular heart...
- The Defense Logistics Agency awarded Amerisourcebergen Drug Corp a delivery order valued at $3,535.90 for Procainamide 1 gram/10 milliliter vials on January 30, 2026, with an ultimate completion date of February 2, 2026. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed in Conshohocken, Pennsylvania. The award is issued under Amerisourcebergen Drug Corp's parent company, Cencora, Inc. (doing business as Amerisourcebergen), which holds a...
- The Defense Logistics Agency awarded a $1,513.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram per 10 milliliter vials on January 28, 2026, with an ultimate completion date of January 29, 2026. This non-set-aside contract was competitively awarded and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Procainamide is an antiarrhythmic medication used to treat abnormal heart rhythms and is a critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Procainamide 1 gram/10 milliliter vials totaling $9,116.21 with an ultimate completion date of January 30, 2026. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award was fulfilled by AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, where the product will be...
- The Defense Logistics Agency awarded a delivery order valued at $4,276.76 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 29, 2026, with an ultimate completion date of January 30, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Procainamide is a cardiac antiarrhythmic medication commonly used in military and...
- The Defense Logistics Agency awarded a delivery order valued at $4,532.88 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 mL vials on November 26, 2025, with an ultimate completion date of November 28, 2025. This competitive, non-set-aside contract utilizes firm fixed-price pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,187.81 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials. This is a firm fixed-price contract with an ultimate completion date of January 12, 2026, and represents a competitively awarded, non-set-aside procurement. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. AmerisourceBergen Drug Corp is a subsidiary of...
- SPE2DR25D7005Indefinite Delivery Contract
- SPE2DR25D7005-SPE2DR26F3EZGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,158.13 to AmerisourceBergen Drug Corp for the supply of Procainamide 1 gram/10 milliliter vials on January 29, 2026. This firm fixed-price delivery order, which is not set-aside, represents a single task order under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate completion date of January 30, 2026. Procainamide is an antiarrhythmic medication used to treat abnormal heart rhythms and is a critical pharmaceutical commodity for military healthcare systems. This delivery order is executed under AmerisourceBergen's comprehensive IDC with DLA Troop Support Medical, valued at up to $999,999,999 and extending through December 2026. AmerisourceBergen, a subsidiary of parent company Cencora, Inc., serves as a major pharmaceutical distributor and prime vendor for federal medical procurement, supplying an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military treatment facilities and veteran healthcare programs worldwide. The non-set-aside status reflects the company's ability to compete and win through full and open competition on federal pharmaceutical contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 1/28/26 |